» Articles » PMID: 16123332

Loss of Pentameric Symmetry in C-reactive Protein Induces Interleukin-8 Secretion Through Peroxynitrite Signaling in Human Neutrophils

Overview
Journal Circ Res
Date 2005 Aug 27
PMID 16123332
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Plasma levels of C-reactive protein (CRP), nitrotyrosine, and interleukin-8 (IL-8) are known predictors of acute cardiovascular events. Peroxynitrite (ONOO-) may function as an intracellular signal for the production of IL-8; however, it is not known whether CRP regulates these events. Emerging evidence suggests that some bioactivities of CRP are expressed only when the pentameric structure of CRP is lost, resulting in formation of monomeric or modified CRP (mCRP). We studied the impact of human native CRP and bioengineered mCRP that cannot rearrange into the pentameric structure on ONOO- formation and ONOO--mediated IL-8 gene expression in human leukocytes. Incubation of human whole blood or isolated neutrophils with mCRP (0.1 to 100 microg/mL) for 4 hours increased IL-8 gene expression and secretion that was blocked approximately 70% by the NO synthase inhibitor Nomega-nitro-L-arginine methyl ester (L-NAME). In neutrophils, mCRP simultaneously increased superoxide production and endothelial nitric oxide synthase-mediated NO formation, leading to enhanced ONOO- formation, and consequently activation of nuclear factor-kappaB and activator protein-1. Native CRP had no detectable effect at 4 hours, whereas it enhanced IL-8 release after a 24-hour incubation that was blocked by L-NAME. An anti-CD16 antibody, but not an anti-CD32 antibody, produced 60% to 70% reductions in mCRP-stimulated NO formation and IL-8 release (both P<0.05). These results suggest that loss of the pentameric symmetry in CRP, resulting in formation of mCRP, leads to IL-8 release from human neutrophils via peroxynitrite-mediated activation of nuclear factor-kappaB and activator protein-1.

Citing Articles

C-reactive protein: structure, function, regulation, and role in clinical diseases.

Zhou H, Tang Y, Xu T, Cheng B Front Immunol. 2024; 15:1425168.

PMID: 38947332 PMC: 11211361. DOI: 10.3389/fimmu.2024.1425168.


Interorgan communication with the liver: novel mechanisms and therapeutic targets.

Zhao J, Zhang X, Li Y, Yu J, Chen Z, Niu Y Front Immunol. 2023; 14:1314123.

PMID: 38155961 PMC: 10754533. DOI: 10.3389/fimmu.2023.1314123.


C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians.

Mouliou D Diseases. 2023; 11(4).

PMID: 37873776 PMC: 10594506. DOI: 10.3390/diseases11040132.


A biofunctional review of C-reactive protein (CRP) as a mediator of inflammatory and immune responses: differentiating pentameric and modified CRP isoform effects.

Olson M, Hornick M, Stefanski A, Albanna H, Gjoni A, Hall G Front Immunol. 2023; 14:1264383.

PMID: 37781355 PMC: 10540681. DOI: 10.3389/fimmu.2023.1264383.


Pentameric C-reactive protein is a better prognostic biomarker and remains elevated for longer than monomeric CRP in hospitalized patients with COVID-19.

Hopkins F, Nordgren J, Fernandez-Botran R, Enocsson H, Govender M, Svanberg C Front Immunol. 2023; 14:1259005.

PMID: 37724104 PMC: 10505432. DOI: 10.3389/fimmu.2023.1259005.